This technology comprises bifunctional compounds based on oxetane-substituted sulfoxides, sulfides, and sulfones that serve dual roles as radiation protectors/mitigators and aqueous solubility enhancers for organic compounds. The compounds feature a core structure where a sulfoxide, sulfide, or sulfone group is connected to oxetane rings with variable substituents, and in some cases, nitrogen atoms replace the oxygen in the ring. The synthesis of the lead compound, MMS350, involves a multi-step process starting from 3-tosyloxymethyl-3-methyloxetane, progressing through a sulfide intermediate, and final oxidation. This molecule has been shown to improve the solubility of drugs while also demonstrating low toxicity and protective effects against various types of radiation-induced damage.
Description
This technology is differentiated by its unique combination of enhanced solubility and effective radiation protection in a single molecular framework. Unlike traditional solubilizers such as DMSO, MMS350 operates via cosolvent properties and exhibits a favorable log P value of -0.87, ensuring better water compatibility. Its dual-action mechanism not only mitigates radiation damage but also improves drug formulation, making it a versatile tool in both pharmaceutical development and radiation therapy applications.
Applications
- Pharmaceutical solubility enhancer
- Radiation countermeasure treatment
- Drug formulation adjuvant
- Radiation damage mitigator
Advantages
- Enhances aqueous solubility of poorly soluble drugs, outperforming traditional solvents like DMSO.
- Acts as a dual-purpose agent that protects against and mitigates radiation-induced damage.
- Demonstrates a low toxicity profile in both in vitro and in vivo studies.
- Offers versatility in chemical structure, allowing for varied substitutions and optimized performance.
- Facilitates improved drug delivery and more reliable high-throughput screening in pharmaceutical development.
IP Status
https://patents.google.com/patent/US9546144B2
